Lyme vaccine advances in Europe, but UK chikungunya setback and wider loss weigh
Lyme vaccine clears first European regulatory hurdle The EMA validated Pfizer and Valneva's application for their Lyme disease vaccine, starting the official review. If approved, it would be the first such vaccine in Europe and a major future revenue source for Valneva, which is the development partner. This is the biggest potential value driver in the period.
This is the main positive force behind VLA.PA, a new regulatory milestone for its most advanced pipeline asset.
UK pulls chikungunya vaccine approval over safety UK regulators revoked the marketing authorization for Valneva's chikungunya vaccine Ixchiq, and the company will not appeal. Valneva says the financial hit is minimal, but losing a whole approved market removes a revenue stream and raises questions about the product's safety profile elsewhere.
This is a new negative event that directly pressures VLA.PA shares and its commercial outlook.
First-half loss widens sharply on lower sales Valneva's net loss ballooned to €63.3 million from €20.8 million a year earlier, hurt by lower product sales, weak manufacturing volumes, and one-off costs including IXCHIQ contract termination and inventory write-offs. Cash rose to €121.5 million, and full-year guidance was kept, but profitability remains a concern.
The widening loss and weak sales are a core fundamental drag on the stock, even as cash and guidance hold.
Lyme trial data strong but not statistically clean The Phase 3 VALOR trial showed over 70% efficacy, but the primary analysis narrowly missed its required statistical threshold, while a second analysis passed. This means approval is not guaranteed and the review could face scrutiny, tempering the optimism around the EMA filing.
It is the key counterweight to the positive Lyme news, explaining why the regulatory win is not a sure thing.